Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).

This open-label, non-randomized, parallel-group trial investigated the pharmacokinetics of raltitrexed (Tomudex, formerly ZD1694) after a single intravenous dose of 3.0 mg m(-2), comparing eight cancer patients with mild to moderate renal impairment (creatinine clearance 25-65 ml min(-1)) with eight...

Descripción completa

Detalles Bibliográficos
Autores principales: Judson, I., Maughan, T., Beale, P., Primrose, J., Hoskin, P., Hanwell, J., Berry, C., Walker, M., Sutcliffe, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062997/
https://www.ncbi.nlm.nih.gov/pubmed/9820178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062997/
https://www.ncbi.nlm.nih.gov/pubmed/9820178

Ejemplares similares